CCR8 and neoplasm: Kidani et al. showed that administering anti-CCR8 monoclonal antibodies (mAb) to tumor-bearing mice results in CD8+ effector T-cell expansion, less T-cell exhaustion, and tumor immunity when mice were rechallenged with the same tumor cell line.